Compare USBC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USBC | CCCC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | | United States |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.2M | 185.1M |
| IPO Year | N/A | 2020 |
| Metric | USBC | CCCC |
|---|---|---|
| Price | $0.36 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.80 |
| AVG Volume (30 Days) | 435.9K | ★ 1.5M |
| Earning Date | N/A | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $0.38 | $1.09 |
| 52 Week High | $1.97 | $3.64 |
| Indicator | USBC | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 72.18 |
| Support Level | N/A | $2.26 |
| Resistance Level | $0.53 | $2.85 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 4.84 | 78.26 |
USBC Inc is a multi-disciplinary technology company that is an innovator in digital financial technologies. The company develops financial services including digital assets and banking solutions, as well as non-invasive health monitoring research. USBC has implemented a Bitcoin treasury strategy to support development and research across its various divisions. A key focus is the further development of its tokenized deposit program, a tokenized representation of a U.S.-dollar-denominated bank deposit account that operates on blockchain technology and is embedded with digital identity, alongside its legacy non-invasive sensor technology business, with the objective of creating long-term shareholder value in an evolving financial landscape.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.